Evidence map›Paper›PMID 37195572›Full record

ArticleInternational urology and nephrology2024

Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.

Jichao Guan, Shuwen Gong, Qiuli He, Xiaoling Wang, Shuijuan Shen, Xiujuan Wu, Juanping Shan, Tujian Gong, Yanru Yang, Haiying Xie

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jichao GuanShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Shuwen GongShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Qiuli HeShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Xiaoling WangShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Shuijuan ShenShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Xiujuan WuShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Juanping ShanShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Tujian GongShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Yanru YangShaoxing People's Hospital, Shaoxing, Zhejiang, China.
Haiying XieShaoxing People's Hospital, Shaoxing, Zhejiang, China. xiaoxia399@aliyun.com.
Shaoxing People's Hospital · CN

Funding

Health Science and Technology Program of Zhejiang Province of China 2022KY1300Health Science and Technology Program of Zhejiang Province of China 2022KY396
6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) is an important cause of morbidity and mortality in peritoneal dialysis (PD) patients. Cardiovascular calcification (CVC) is highly prevalent in PD patients and could predict their cardiovascular mortality. Soluble urokinase plasminogen activator receptor (suPAR) is closely associated with coronary artery calcification in hemodialysis patients and is an important predictor of CVD. However, the role of suPAR in PD patients is poorly understood. We investigated the relationship between serum suPAR and CVC in PD patients.

methodsAbdominal aortic calcification (AAC) was assessed by lateral lumbar radiography, coronary artery calcification (CAC) by multi-slice computed tomography, and cardiac valvular calcification (ValvC) by echocardiography. CVC was defined as confirmed presence of calcification in one site (AAC, CAC, or ValvC). Patients were divided into CVC group and non-CVC group. Demographic characteristics, biochemical variables, comorbidities, PD regimen, serum suPAR, and medication were compared between the two groups. Logistic regression was conducted to determine association between serum suPAR and presence of CVC. The receiver-operator curve (ROC) was plotted to calculate the area under the curve (AUC) for suPAR to identify CVC and ValvC.

resultsOf 226 PD patients, 111 (49.1%) had AAC, 155 (68.6%) had CAC, and 26 (11.5%) had ValvC. There were significant differences in age, BMI, diabetes, white blood cell, phosphorus, hs-CRP, suPAR, time on dialysis, total volume of dialysate, ultrafiltration, volume of urine, and Kt/V between CVC and non-CVC group. Serum suPAR was associated with CVC by multivariate logistic regression analysis in PD patients, especially in elderly patients. The levels of serum suPAR were closely related to the degree of AAC, CAC, and ValvC in PD patients. The incidence of CVC was higher in patients with higher levels of suPAR. The ROC curve showed that serum suPAR had a predictive value for CVC (AUC = 0.651), especially for ValvC (AUC = 0.828).

conclusionCardiovascular calcification is prevalent in PD patients. High levels of serum suPAR are associated with cardiovascular calcification in PD patients, especially in elderly patients.

Indexed as

CalcinosisCardiovascular DiseasesCoronary Artery DiseasePeritoneal DialysisBiomarkersHumansReceptors, Urokinase Plasminogen ActivatorRisk FactorsBiomarkersReceptors, Urokinase Plasminogen ActivatorCardiovascular calcificationCardiovascular diseasePeritoneal dialysisSoluble urokinase plasminogen activator receptor

Identifiers

PMID37195572
OpenAlexW4376872875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.